GI Innovation Inc
KOSDAQ:358570
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8 970
24 000
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
GI Innovation Inc
Common Shares Outstanding
GI Innovation Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Common Shares Outstanding
â‚©44.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Celltrion Inc
KRX:068270
|
Common Shares Outstanding
â‚©207.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
||
SK Bioscience Co Ltd
KRX:302440
|
Common Shares Outstanding
â‚©76.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
||
H
|
Hugel Inc
KOSDAQ:145020
|
Common Shares Outstanding
â‚©11m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Common Shares Outstanding
â‚©10.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
KOSDAQ:196170
|
Common Shares Outstanding
â‚©53.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Common Shares Outstanding?
Common Shares Outstanding
44.1m
KRW
Based on the financial report for Dec 31, 2023, GI Innovation Inc's Common Shares Outstanding amounts to 44.1m KRW.
What is GI Innovation Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
0%
Over the last year, the Common Shares Outstanding growth was 0%.